The Use of Lentinan for Treating Gastric Cancer

Overview

Journal Anticancer Agents Med Chem

Publisher Bentham Science Publishers

Specialties Chemistry
Oncology

Date 2012 Oct 25

PMID 23092289

Citations 58

Authors

Kenji Ina

Takae Kataoka

Takafumi Ando

Affiliations

Soon will be listed here.

Abstract

Natural compounds containing fungal β-glucans have been used to improve general health for thousands of years in China and Japan. Lentinan, the backbone of β-(1, 3)-glucan with β-(1, 6) branches, is one of the active ingredients purified from Shiitake mushrooms and has been approved as a biological response modifier for the treatment of gastric cancer in Japan. Despite recent advances in chemotherapeutic agents, unresectable or recurrent gastric cancer remains an incurable disease, with survival rates being far from satisfactory. Recent clinical studies have shown that chemo-immunotherapy using lentinan prolongs the survival of patients with advanced gastric cancer, as compared to chemotherapy alone. In addition, trastuzumab, an antibody against HER2/neu growth factor receptor, has been used for the treatment of gastric cancer in combination with cytotoxic chemotherapeutic agents. Lentinan may exert a synergistic action with anti-cancer monoclonal antibodies to activate complement systems through the mechanism of antibody-dependent cellular cytotoxicity and complement dependent cytotoxicity. Because a better understanding of its biological activities should enable us to use lentinan more efficiently in the treatment of gastric cancer, immunological effects provided by β-glucans, a possible mode of action of lentinan, and its clinical application including future potential uses are discussed in the present review.

Citing Articles

Mechanistic insights into the role of traditional Chinese medicine in treating gastric cancer.

Chen Z, Yu T, Wang Y, Li J, Zhang B, Zhou L Front Oncol. 2025; 14:1443686.

PMID: 39906672 PMC: 11790455. DOI: 10.3389/fonc.2024.1443686.

Nutritional, Nutraceutical, and Medicinal Potential of Fr.: A Comprehensive Review.

Kumar A, Devi R, Dhalaria R, Tapwal A, Verma R, Rashid S Food Sci Nutr. 2025; 13(1):e4641.

PMID: 39803245 PMC: 11717058. DOI: 10.1002/fsn3.4641.

Chinese Medicines and Natural Medicine as Immunotherapeutic Agents for Gastric Cancer: Recent Advances.

Zhang Z, Chen Z, Que Z, Fang Z, Zhu H, Tian J Cancer Rep (Hoboken). 2024; 7(9):e2134.

PMID: 39233637 PMC: 11375283. DOI: 10.1002/cnr2.2134.

β-glucan: a potent adjuvant in immunotherapy for digestive tract tumors.

Wang M, Pan J, Xiang W, You Z, Zhang Y, Wang J Front Immunol. 2024; 15:1424261.

PMID: 39100668 PMC: 11294916. DOI: 10.3389/fimmu.2024.1424261.

Lentinan mitigates pemetrexed chemoresistance by the PI3K/Akt pathway in non-small cell lung cancer.

Tian P, Du D, Yang L, Zhou N, Tao L Cell Biochem Biophys. 2024; 82(2):1421-1431.

PMID: 38750384 DOI: 10.1007/s12013-024-01296-8.

References

Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S . Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. J Clin Oncol. 2012; 30(8):837-42. DOI: 10.1200/JCO.2011.37.3472. View

Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J . Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res. 2009; 29(7):2739-45. View

Kamangar F, Dores G, Anderson W . Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24(14):2137-50. DOI: 10.1200/JCO.2005.05.2308. View

Donskov F, von der Maase H . Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J Clin Oncol. 2006; 24(13):1997-2005. DOI: 10.1200/JCO.2005.03.9594. View

van de Winkel J, Capel P . Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today. 1993; 14(5):215-21. DOI: 10.1016/0167-5699(93)90166-I. View

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Carter P . Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer. 2002; 1(2):118-29. DOI: 10.1038/35101072. View

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C . Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?. Br J Cancer. 2006; 94(2):259-67. PMC: 2361112. DOI: 10.1038/sj.bjc.6602930. View

Wohrer S, Raderer M, Hejna M . Palliative chemotherapy for advanced gastric cancer. Ann Oncol. 2004; 15(11):1585-95. DOI: 10.1093/annonc/mdh422. View

10.

Ina K, Furuta R, Kataoka T, Kayukawa S, Yoshida T, Miwa T . Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy. World J Clin Oncol. 2011; 2(10):339-43. PMC: 3191325. DOI: 10.5306/wjco.v2.i10.339. View

11.

Clynes R, Towers T, Presta L, Ravetch J . Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000; 6(4):443-6. DOI: 10.1038/74704. View

12.

Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri G, Bernasconi S . Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000; 95(12):3900-8. View

13.

Sastre J, Garcia-Saenz J, Diaz-Rubio E . Chemotherapy for gastric cancer. World J Gastroenterol. 2006; 12(2):204-13. PMC: 4066028. DOI: 10.3748/wjg.v12.i2.204. View

14.

Underhill D, Rossnagle E, Lowell C, Simmons R . Dectin-1 activates Syk tyrosine kinase in a dynamic subset of macrophages for reactive oxygen production. Blood. 2005; 106(7):2543-50. PMC: 1895265. DOI: 10.1182/blood-2005-03-1239. View

15.

Nakazato H, Koike A, Saji S, Ogawa N, Sakamoto J . Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Study Group of Immunochemotherapy with PSK for Gastric Cancer. Lancet. 1994; 343(8906):1122-6. DOI: 10.1016/s0140-6736(94)90233-x. View

16.

Slamon D, Clark G, Wong S, Levin W, Ullrich A, McGuire W . Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. DOI: 10.1126/science.3798106. View

17.

Matsuoka H, Seo Y, Wakasugi H, Saito T, Tomoda H . Lentinan potentiates immunity and prolongs the survival time of some patients. Anticancer Res. 1997; 17(4A):2751-5. View

18.

Rogers N, Slack E, Edwards A, Nolte M, Schulz O, Schweighoffer E . Syk-dependent cytokine induction by Dectin-1 reveals a novel pattern recognition pathway for C type lectins. Immunity. 2005; 22(4):507-17. DOI: 10.1016/j.immuni.2005.03.004. View

19.

Young S, Ye J, Frazer D, Shi X, Castranova V . Molecular mechanism of tumor necrosis factor-alpha production in 1-->3-beta-glucan (zymosan)-activated macrophages. J Biol Chem. 2001; 276(23):20781-7. DOI: 10.1074/jbc.M101111200. View

20.

Czop J, Austen K . A beta-glucan inhibitable receptor on human monocytes: its identity with the phagocytic receptor for particulate activators of the alternative complement pathway. J Immunol. 1985; 134(4):2588-93. View